BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med 2021;10:991. [PMID: 33801203 DOI: 10.3390/jcm10050991] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Barsch M, Salié H, Mesesan A, Bengsch B. T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy. Liver Cancer International 2023. [DOI: 10.1002/lci2.72] [Reference Citation Analysis]
2 Rivoltini L, Bhoori S, Camisaschi C, Bergamaschi L, Lalli L, Frati P, Citterio D, Castelli C, Mazzaferro V. Y(90)-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers. Gut 2023;72:406-7. [PMID: 35508369 DOI: 10.1136/gutjnl-2021-326869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lu X, Song B, Weng W, Su B, Wu H, Cheung AKL, Zhang T, Gao Y. Characteristics of CD8(+) Stem Cell-Like Memory T Cell Subset in Chronic Hepatitis C Virus Infection. Viral Immunol 2023;36:25-32. [PMID: 36346310 DOI: 10.1089/vim.2022.0079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rennert C, Lang‐meli J, Gromak M, Hofmann M, Thimme R, Roehlen N. Perspectives for novel therapeutic concepts in hepatocellular carcinoma targeting the stromal and innate immune microenvironment. Liver Cancer International 2022. [DOI: 10.1002/lci2.70] [Reference Citation Analysis]
5 Liang J, Wang J, Zeng J, Bai Z, Zheng Z, Zheng Y, Jiang F, Wu D. The Landscape of Early Growth Response Family Members 1-4 in Hepatocellular Carcinoma: Their Biological Roles and Diagnostic Utility. Dis Markers 2022;2022:3144742. [PMID: 36046377 DOI: 10.1155/2022/3144742] [Reference Citation Analysis]
6 Lupberger J, Baumert TF. Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges. J Clin Med 2021;11:208. [PMID: 35011949 DOI: 10.3390/jcm11010208] [Reference Citation Analysis]
7 Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, Yang X, Wang B. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med 2021;10:7977-87. [PMID: 34605616 DOI: 10.1002/cam4.4312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wu Z, He L, Yang L, Fang X, Peng L. Potential Role of NEU1 in Hepatocellular Carcinoma: A Study Based on Comprehensive Bioinformatical Analysis. Front Mol Biosci 2021;8:651525. [PMID: 34513919 DOI: 10.3389/fmolb.2021.651525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Woller N, Engelskircher SA, Wirth T, Wedemeyer H. Prospects and Challenges for T Cell-Based Therapies of HCC. Cells 2021;10:1651. [PMID: 34209393 DOI: 10.3390/cells10071651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Umemura T, Joshita S, Saito H, Wakabayashi SI, Kobayashi H, Yamashita Y, Sugiura A, Yamazaki T, Ota M. Investigation of the Effect of KIR-HLA Pairs on Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic Patients. Cancers (Basel) 2021;13:3267. [PMID: 34209910 DOI: 10.3390/cancers13133267] [Reference Citation Analysis]